Johnson & Johnson appears to have listened to President Donald Trump’s State of the Union Address Tuesday.
Trump, in a portion of his speech devoted to health care, called on pharmaceutical companies to reveal “real prices” – presumably a reference to an administration proposal that would require drugmakers to show the full sticker price, or list price, of medicines in TV ads. J&J is jumping the gun, with plans to voluntarily disclose this price in its direct-to-consumer commercials, according to a blog post released Thursday. The company will start with ads for blood thinner Xarelto by late March, and then move on to other medicines. It’s the first drugmaker to announce such a step.
The move seems designed to give Trump a win, and it appears to have earned J&J a bit of goodwill: Health and Human Services Secretary Alex Azar released an approving statement Thursday evening. But it won’t do anything to dismiss more threatening drug-price proposals that still loom for pharma, and may not give patients much clarity, either.
The idea behind the administration’s proposal is that by requiring drugmakers to prominently display their often sky-high list prices, it may shame them into lowering them. Pharma opposes it, arguing that list prices are meaningless to most Americans because health plans often negotiate huge discounts with drugmakers and consumers usually pay only a portion of a lower price themselves. In fact, drug companies have claimed that showing an inflated price in TV ads may discourage people from seeking needed medicines.
In a mitigating tactic, Johnson & Johnson’s planned price disclosure will include an estimate of what typical patients actually pay for drugs, something that Trump’s proposed mandate doesn’t include. That will make the much higher list price much less scary. But it also could confuse patients exposed to a higher-than-average price because they pay co-insurance on some drugs or have a high-deductible plan. It’s tough to fit those nuances into a 30-second TV spot.